PureTech Health plc
NASDAQ:PRTCBiotechnology
+$0.45 today
- Market cap
- $423.09M
- Beta
- 0.79
- P/E (TTM)
- -0.4
- EPS (TTM)
- -$45.37
Volume 0.01M
Average 0.01M
PRTC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
PureTech Health plcNASDAQ: PRTC
EBITDA · Q4 FY2025 · quarter ended Dec 2025
EBITDA turns negative
Q4 FY2025 EBITDA was -$48.75M, compared with $101.97M a year earlier.
Context
- EBITDA amounted to 1326.5% of revenue in FY2025, up 552.2 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of -$9.9M (+84.0%) for the fiscal year ending Dec 2026, a step up from the -265.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$48.75M— QoQ
- Last fiscal yearDec 2025
- -$61.8M-265.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -147.8% | — | — |
| 1 year | -265.3% | +84.0% | +349.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (61.8M) USD
- Year-over-year change
- -265.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (61.8M) | -265.3% |
| FY2024 | 2024-12-31 | 37.38M | +421.5% |
| FY2023 | 2023-12-31 | (11.63M) | +93.8% |
| FY2022 | 2022-12-31 | (188.91M) | -807.5% |
| FY2021 | 2021-12-31 | 26.7M | — |
EBITDA vs competitors
How PRTC compares with its peers on the latest reported figures
- PRTC's FY2025 EBITDA of -$61.8M is the 3rd highest of the 11 companies compared; the peer median is -$144.62M.
- Its year-over-year change of -265.3% is the lowest of 11, against a peer median of -6.3%.
- EBITDA amounts to 1326.5% of revenue for PRTC, versus a peer median of 291.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$43.15M | -177.1% | — | 291.9% | |
| LTM Mar 2026 | -$53.46M | -44.4% | — | — | |
| FY2025 | -$61.8M | -265.3% | — | 1326.5% | |
| LTM Mar 2026 | -$83.2M | +13.7% | — | 105.1% | |
| LTM Mar 2026 | -$95.45M | -22.9% | — | — | |
| LTM Mar 2026 | -$99.13M | -3.1% | — | 5352.8% | |
| LTM Mar 2026 | -$190.1M | -38.9% | — | — | |
| LTM Mar 2026 | -$194.47M | +21.0% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$217.64M | +15.4% | — | — |
| LTM Mar 2026 | -$230.8M | +3.4% | — | 249.3% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$442.87M | -9.5% | — | 5986.3% |
| Peer median (excluding PRTC) | -$144.62M | -6.3% | — | 291.9% | |
Competitors are the stored peer set for PRTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.98M | 2.09M | 3.33M | 4.83M | 4.66M |
| Cost of Revenue | 110.47M | 152.43M | 4.93M | 3.57M | 3.36M |
| Gross Profit | (100.49M) | (136.82M) | (1.6M) | 1.26M | 4.66M |
| Gross Margin | -1007.0% | -6546.2% | -48.1% | 26.0% | 100.0% |
| Research & Development | 81.52M | 116.11M | 96.24M | 54.28M | 45.74M |
| Selling, General & Admin | 30.76M | 35.67M | 48.36M | 27.49M | 20.65M |
| Operating Expenses | 160.26M | 60.99M | 54.55M | 140.41M | 103.18M |
| Depreciation & Amortization | 7.24M | 8.89M | 4.93M | 3.57M | 3.35M |
| EBITDA | 26.7M | (188.91M) | (11.63M) | 37.38M | (61.8M) |
| EBITDA Margin | 267.6% | -9038.9% | -349.2% | 774.3% | -1326.5% |
| Operating Income | (150.28M) | (197.81M) | (146.2M) | (136.1M) | (98.53M) |
| Operating Margin | -1506.0% | -9464.4% | -4390.4% | -2818.9% | -2114.7% |
| Interest Income | 214K | 5.8M | 16.01M | 22.67M | 13.05M |
| Interest Expense | 4.71M | 3.95M | 13.49M | 10.04M | 45.78M |
| Other Income / Expenses | 91.33M | 105.02M | 110.1M | 159.87M | (12.4M) |
| Income Before Tax | (58.95M) | (92.78M) | (36.1M) | 23.77M | (110.93M) |
| Pre-Tax Margin | -590.8% | -4439.4% | -1084.2% | 492.4% | -2380.9% |
| Income Tax Expense | 3.76M | (55.72M) | 30.53M | (4.01M) | (842K) |
| Net Income | (60.56M) | (50.36M) | (65.7M) | 53.51M | (109.74M) |
| Net Margin | -606.9% | -2409.3% | -1972.9% | 1108.3% | -2355.4% |
| EPS (Basic) | (2.10) | (1.80) | (2.40) | 2.00 | (46.00) |
| EPS (Diluted) | (2.10) | (1.80) | (2.40) | 2.00 | (46.00) |
| Weighted Avg Shares | 28.66M | 27.97M | 27.63M | 26.97M | 2.41M |
| Weighted Avg Shares (Diluted) | 28.66M | 28.48M | 27.63M | 26.97M | 2.41M |
PureTech Health plc
NASDAQ:PRTC
Intrinsic Alpha fair value
Locked
Current Price
$17.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.